Share This

Public company info - Golden Throat Holdings Group Co. Ltd. , 06896.HK
Input the stock code or the company name     Search  
 
 Profile   Information   Data   Financial Ratios   Profit Loss   Cash Flow   Balance   Earnings   Dividend 

Golden Throat Holdings Group Co. Ltd., 06896.HK - Company Profile
Chairman JIANG Peizhen
Share Issued (share) 739,000,000
Par Currency U.S. Dollar
Par Value 2.5E-5
Industry Medicine
Corporate Profile Business Summary: The Group was principally involved in the manufacture and sale of pharmaceutical, healthcare food and other products. Performance for the year: Revenue increased by approximately RMB102.9 million or 14.8% to approximately RMB797.1 million, as compared to the year ended 31 December 2018. Gross profit increased by approximately RMB82.0 million or 15.9% to approximately RMB598.5 million, as compared to the year ended 31 December 2018. Earnings before interest, taxes, depreciation and amortisation increased by approximately RMB78.3 million or 48.7% to approximately RMB239.2 million, as compared to the year ended 31 December 2018. Profit attributable to equity holders of the Company increased by approximately RMB65.4 million or 64.0% to approximately RMB167.6 million, as compared to the year ended 31 December 2018. Business Review Golden Throat Lozenges (OTC) – over-the-counter medicine The Group’s flagship product is Golden Throat Lozenges (OTC), which was launched in 1994. It is a type of lozenge mainly designed to relieve symptoms of sore and dry throat and hoarse voice caused by acute pharyngitis. Golden Throat Lozenges (OTC) was approved as over-the-counter medicine by the CFDA, as such they can be purchased by the public in pharmacies without requiring the prescription of a qualified medical professional. As of 31 December 2019, Golden Throat Lozenges (OTC) were exported to the United States, Canada, Russia, the European Union, Australia, Southeast Asia, Middle East, Mexico, Africa, and Mongolia, a newly explored export country in 2019, across five continents of the world. As of 31 December 2019, the Group’s revenue of Golden Throat Lozenges (OTC) accounted for approximately 90.5% of its total revenue for the year ended 31 December 2019. Golden Throat Lozenge Series Products – Food The Group’s other key products are Golden Throat Lozenge Series Products, which include seven products comprising of Dule Lozenges (都樂含片), sugar-free Dule Lozenges and five other sugar-free flavours of this series, namely orange (香橙), fructus momordicae (羅漢果), chrysanthemum (桑菊), American ginseng (西洋參) and hawthorn (山楂). A major difference between Golden Throat Lozenges (OTC) and Golden Throat Lozenge Series Products is that the former is approved as over-the-counter medicine, whereas the latter is approved as food products. The sugar-free series of Golden Throat Lozenge Series Products was launched in 2013, which supplements the Group’s original sales channel and provides consumers with more diversified choices in response to consumer differentiation. In 2019, Golden Throat Lozenge Series Products was newly exported to Japan, United Kingdom, the Netherlands, Italy, Spain, Portugal and Germany. As of 31 December 2019, Golden Throat Lozenge Series Products were exported to 17 countries and regions. As of 31 December 2019, the Group’s revenue of Golden Throat Lozenges Series Products accounted for approximately 8.4% of its total revenue for the year ended 31 December 2019. Other Products As of 31 December 2019, the Group’s revenue of other products accounted for approximately 1.1% of its total revenue for the year ended 31 December 2019. Two of the Group’s other products are Yinxingye Tablet (銀杏葉片) and Herbal Vegetable Beverages. Yinxingye Tablet is mainly designed to facilitate blood circulation, remove blood stasis and dredge energy channels and was approved as a prescription medicine by the CFDA, while the main function of Herbal Vegetable Beverages is soothing voice and relieving sore throats. Research and Development The Group’s business has significantly benefited from its strong track record in research and development. Since 1994, the Group has successfully developed 31 new products for which it has obtained manufacturing permits, amongst which, eight are pharmaceutical products (including Jinyin Sanqi Capsule (金銀三 七膠囊)), 21 are food products, one is a health supplement and one is a medical apparatus product. The Group’s research and development activities are conducted both in-house and through collaborations with external research institutions, such as hospitals, institutes for drug research and other companies. As at 31 December 2019, the Group’s research and development team consisted of approximately 270 people. Prospects: The Group will continue to seek to strengthen its leading position in the lozenge market and continue to expand its market share in the PRC pharmaceutical and food markets. Moreover, the Group will aim to increase its production capacities, expand its product portfolio and strengthen its research and development capabilities. It will enhance its food and other pharmaceutical businesses and promote synergies across different product segments. The Group will aim to enhance its brand recognition through effective and targeted marketing efforts, and will continue to expand its distribution network, to refine associated infrastructure and to leverage on its existing distribution network to promote different products.

Information from the financial statements of listed companies

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.